# Medical Biotechnology Quick Overview

Douglas Beach

► To cite this version:

Douglas Beach. Medical Biotechnology Quick Overview. Cellular & Molecular Medicine: Open access, 2021, Medical Biotechnology Quick Overview, 7 (6). [https://hal.science/hal-04032191](https://hal.science/hal-04032191)

HAL Id: hal-04032191

https://hal.science/hal-04032191

Submitted on 16 Mar 2023

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
# Medical Biotechnology Quick Overview

## Douglas Beach*

Editorial Office, Cellular & Molecular
Medicine, Germany

### Abstract

The Entrez system allows users to search and get information from 37 different databases. The E-utilities serve as the Entrez system's programming interface. Biotechnology is a vast field of biology that involves the development or manufacture of items using live systems and creatures. It frequently intersects with allied scientific subjects, depending on the tools and applications used. Biotechnology has developed to embrace new and varied disciplines such as genomics, recombinant gene methods, applied immunology, and the creation of pharmacological medicines and diagnostic tests in the late twentieth and early twenty-first centuries. Custom versions of the BLAST programme, designed to search particular data sets, are used to supplement many of the Web applications. Bioengineering, on the other hand, is often considered of as a related science that focuses on higher systems techniques (rather than directly modifying or employing biological components) for interacting with and exploiting living things. The application of engineering and natural science concepts to tissues, cells, and molecules is known as bioengineering. This may be defined as the use of information gained by working with and altering biology to produce a product that improves plant and animal functionality.

**Keywords:** BLAST; biology; immunology

**\*Corresponding author:**

Douglas Beach

<figure><img src="image_2.png" /></figure>

douglas.bechr@medicine.edu

Editorial Office, Cellular & Molecular
Medicine, Germany

**Citation:** Beach D (2021) Medical Biotechnology Quick Overview. Cell Mol Med. Vol. 7 No. 6: 29.

**Received:** November 11, 2021, **Accepted:** November 24, 2021, **Published:** November 30, 2021

### Introduction

Biotechnology has aided in the development and production of both classic small molecule pharmaceutical medications and biopharmaceuticals (biotechnology-derived drugs). Existing drugs can be manufactured reasonably readily and cheaply using modern biotechnology. Medicines meant to cure human ailments were the first genetically modified items. For instance, Genentech created synthetic humanised insulin in 1978 by combining its gene with a plasmid vector injected into the bacterium Escherichia coli. Insulin, which is frequently used to treat diabetes, was originally taken from butcher animals' pancreas (cattle or pigs). Emerging medicines like gene therapy have been made possible by biotechnology. The application of biotechnology to basic science (for example, the Human Genome Project) has dramatically improved our understanding of biology, and as our scientific knowledge of normal and disease biology has grown, so has our ability to develop new medicines to treat diseases that were previously untreatable. Where available, assembly records also include common names of species, evidence that a prokaryotic dataset was obtained from type material, and reports

of anomalies or other reasons why a dataset was not included in the Reference Sequences (RefSeq) database. Viewing a genome's ideogram and selecting an individual chromosome to view, searching for locations or annotations, uploading external data to user-defined tracks, adding or removing NCBI data tracks, viewing and navigating to features of interest, and finally, viewing a given portion of the selected chromosome along with the currently selected set of data tracks are just a few of the widgets available in GDV. Assembly and GEO (Gene Expression Omnibus) both allow access to GDV, and the access point dictates the specifics of the views.

### Pharmaceuticals with tiny molecules

Our study design was reviewed and approved by the University of Pennsylvania Institutional Review Board. The patient cohort from Pennsylvania Hospital was obtained from the UPHS Cancer Registry with a diagnosis of stage four colon cancer between 2014-2018. A retrospective chart review was conducted using electronic medical records.

Progression-free survival was determined the first date of
documentation diagnosis of metastatic colon cancer to the first The bacteria have been genetically modified to generate enormous amounts of synthetic human insulin at a minimal cost. Emerging therapies such as gene therapy have also been made possible by biotechnology. The application of biotechnology to basic science (for example, the Human Genome Project) has greatly improved our understanding of biology, and as our scientific knowledge of normal and disease biology has grown, so has our ability to develop new medicines to treat diseases that were previously untreatable. The majority of the time, testing is done to look for alterations that are linked to genetic illnesses. A genetic test's results can confirm or rule out a suspected genetic ailment, as well as indicate a person's risk of developing or passing on a genetic disorder. Chemical substances with a molecular weight of 0.1–1 kDa are known as small-molecule medicines. As indicated, they are smaller than biologics or biotherapeutic modalities, which are typically larger than 1 kDa in size. Because of their small size, they have an advantage over biologics in that they can target not only extracellular components such as cell surface receptors or protein domains attached to cell membranes such as glycoproteins, but also intracellular proteins such as various kinases, as they can easily cross the cell's outer plasma membrane. Chemical reactions make them simple to make and they are less expensive than biologics. Aspirin (chemically acetylsalicylic acid) is the most well-known and widely used small-molecule pain, fever, and inflammation medication. Small molecular inhibitors that target quickly developing malignant cells are regarded better possibilities in some cancer treatments than standard chemotherapy and radiation, which can kill both normal and tumour cells in the body, causing difficulties. Several hundred genetic tests were in use as of 2011. Because genetic testing might raise ethical or psychological issues, it is frequently

accompanied by genetic counselling.

## Discussion

Small Molecules and Their Functions as Diagnostic and Therapeutic Agents, a resource that focuses on small molecules and their roles as diagnostic and therapeutic agents, has made numerous enhancements in the last year. Laboratory Chemical Safety Summaries, which offer health and safety data for PubChem Compound records with a GHS danger classification, are now available in PubChem (Globally Harmonized System of Classification and Labeling of Chemicals). These reports are accessible by clicking on the 'Safety Summary' section towards the top of the Compound's record page. The BioAssay record pages were also rebuilt to match the present Compound and Substance sites in terms of mobile friendliness. Numerous improvements have been made to these sites, including enhanced data tables and expanded download possibilities. The PubChem blog has further information on these and other PubChem developments.

## Conclusion

HDAC inhibitors (drugs that suppress the histone deacetylase enzyme) are commonly used to treat tumours including peripheral T-cell lymphoma and cutaneous T-cell lymphoma. The USFDA has authorised just four drugs: romidepsin, vorinostat, belinostat, and panobinostat, but China has approved chidamide. Vorinostat was initially created by a group of Columbia University scientists. In 2006, the FDA authorised it as the first HDAC inhibitor. It was also sold under the brand name Zolinza to treat cutaneous T-cell lymphoma (CTCL). Romidepsin interacts with the disulfide bond within the cell to release a zinc-binding thiol, which reversibly blocks the action of Zn-dependent histone deacetylase.